Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: otterson ga. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE; University of Chicago Phase II Network; Ohio State University. Winegarden JD, et al. Among authors: otterson ga. Ann Oncol. 2004 Jun;15(6):915-20. doi: 10.1093/annonc/mdh215. Ann Oncol. 2004. PMID: 15151948 Free article. Clinical Trial.
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J. Villalona-Calero MA, et al. Among authors: otterson ga. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6086-93. doi: 10.1158/1078-0432.CCR-04-0779. Clin Cancer Res. 2004. PMID: 15447994 Clinical Trial.
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL. Villalona-Calero MA, et al. Among authors: otterson ga. Ann Oncol. 2008 Nov;19(11):1903-9. doi: 10.1093/annonc/mdn412. Epub 2008 Jul 15. Ann Oncol. 2008. PMID: 18632723 Free PMC article. Clinical Trial.
MicroRNAs in the pathogenesis of Lung Cancer.
Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP. Wu X, et al. Among authors: otterson ga. J Thorac Oncol. 2009 Aug;4(8):1028-34. doi: 10.1097/JTO.0b013e3181a99c77. J Thorac Oncol. 2009. PMID: 19474765 Free PMC article. Review.
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. Lam ET, et al. Among authors: otterson ga. Cancer Chemother Pharmacol. 2010 Nov;66(6):1019-29. doi: 10.1007/s00280-010-1252-x. Epub 2010 Jan 28. Cancer Chemother Pharmacol. 2010. PMID: 20107799 Free PMC article. Clinical Trial.
226 results